Clinical trials: Nephropathy, Diabetic
Diabetic Nephropathy
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
This trial is randomized, placebo-controlled, double blind, double dummy, multi-centre trial. Screening period (4 week) Double blind treatment period (16 weeks)
- Trial name
- NCT01726816
- Testing
- Probucol 250mg/day, Probucol 500mg/day
- Where
- 16 sites in South Korea
- Volunteers
- 126 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Exercise
The Study of the Internet Monitoring and Analysis of Exercise to Reduce the Complications of Diabetic Kidney Disease
Microvascular complications are a major complication of diabetes.Diabetic microvascular complications can not only lead to chronic kidney disease and retinopathy, but also affect the quality of life of patients with diabetic…
- Trial name
- NCT03222726
- Testing
- exercise group
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Shanghai Pudong Hospital
Nephropathy, Diabetes
Atrasentan Spermatogenesis and Testicular Function
This study is being conducted to evaluate the effects of Atrasentan on sperm production and testicular function in male subjects with Type 1 or 2 Diabetes and Nephropathy.
- Trial name
- NCT02118714
- Testing
- Atrasentan
- Where
- 13 sites in United States, Germany and 2 more
- Volunteers
- 20 people
- Sponsor
- AbbVie
Diabetic Nephropathy, Diabetic Retinopathy
Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT)
Investigators with the goal of optimizing glycemic and blood pressure control saw type 1 diabetic patients weekly. A control group received 3-4 subcutaneous insulin injections per day; an intravenous insulin pulsed infusion group…
- Trial name
- NCT00594152
- Testing
- CIIIT
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Joslin Diabetes Center
Diabetic Nephropathies
Add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on NT-PRO BNP in Type 2 Diabetics With Nephropathy
This study was designed to assess the efficacy of adding pentoxifylline to losartan in comparison with increasing dose of losartan in type 2 diabetes patients with nephropathy.
- Trial name
- NCT03006952
- Testing
- Pentoxifylline, Losartan
- Where
- Iran
- Volunteers
- 59 people
- Sponsor
- Tehran University of Medical Sciences
Diabetic Kidney Disease
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
The primary objective of this study is to determine the effect of selonsertib (formerly GS-4997) on estimated glomerular filtration rate (eGFR) decline in participants with diabetic kidney disease (DKD).
- Trial name
- NCT02177786
- Testing
- Selonsertib
- Where
- 105 sites in United States, Canada
- Volunteers
- 334 people
- Sponsor
- Gilead Sciences
Diabetic Nephropathy
Sex-specific Association With Kidney Disease
Oxidative stress is involved in the pathophysiology of diabetic nephropathy. The superoxide-generating nicotinamide adenine dinucleotide phosphate-oxidase 2 (NOX2, encoded by the CYBB gene) and the antioxidant enzyme glutathione…
- Trial name
- NCT01810822
- Where
- Brazil
- Volunteers
- 1,396 people
- Sponsor
- University of Sao Paulo General Hospital
Diabetic Nephropathy
6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria
Current research indicates that TTP488 may be a viable agent for the treatment of diabetic nephropathy. The purpose of this study is to determine the safety and efficacy of a six-month regimen of daily orally-administered TTP488…
- Trial name
- NCT00287183
- Testing
- PF-04494700 (TTP488)
- Where
- 19 sites in Canada
- Volunteers
- 110 people
- Sponsor
- Pfizer
Urine VOCs From DKD and Nephrotic Syndrome Pateints
The Biosensor Using the Target Urine VOCs for Detecting DKD Diabetic Kidney Disease
Volatile organic compounds (VOCs) are easily evaporated substances produced by pathophysiologic metabolism and have been utilized in research as potential new biomarkers for differentiating various diseases, acting as the odor…
- Trial name
- VOCs in DKD (NCT07137351)
- Testing
- The Biosensor Using the Target Urine Volatile Organic Compounds
- Where
- Thailand
- Volunteers
- healthy volunteers welcome
- Sponsor
- Suranaree University of Technology
Diabetic Kidney Disease
The Association Between sUCR and the Survival in Patients With DKD
Research Objective: To evaluate the prognostic value of serum urea nitrogen to creatinine ratio (sUCR) in the progression of DKD. Research Design: This study was designed as a multicenter, retrospective cohort study.
- Trial name
- NCT04612595
- Testing
- serum urea nitrogen to creatinine ratio
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Guangdong Provincial People's Hospital
Diabetic Nephropathies, Proteinuria
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
The study is designed to test if the combination of two potent antioxidant nutritional supplements, N-acetylcysteine and the milk thistle extract silibin, is capable of correcting the shedding of urine protein, the oxidative…
- Conditions
- Diabetic Nephropathies, Proteinuria, Oxidative Stress
- Trial name
- NCT00915200
- Testing
- N-acetylcysteine, silibin, high-dose silibin
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes
The goal of this pragmatic trial is to provide Real World Evidence (RWE) on the impact of the result of a polygenic risk prediction test of cardiorenal complications of T2D, so that more patients at high risk of these…
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases, Diabetic Nephropathy Type 2
- Trial name
- GENOCORDIA (NCT06586203)
- Testing
- Polygenic Risk Score
- Where
- 2 sites in Canada
- Volunteers
- 2,714 people
- Sponsor
- Optithera
Diabetes Mellitus, Type 2, Chronic Kidney Disease
Carotid Doppler Screening for Subclinical Atherosclerosis in Diabetic CKD Patients.
This study is being done at Assiut University to look for early signs of hardening of the arteries (atherosclerosis) in people who have both diabetes and chronic kidney disease (CKD).
- Conditions
- Diabetes Mellitus, Type 2, Chronic Kidney Disease, Atherosclerosis
- Trial name
- DiCKD-CAROTID (NCT07266220)
- Volunteers
- 96 people
- Sponsor
- Abdallah Ali Mohammed
Diabetic Nephropathy, T2DM
The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy
Diabetic nephropathy is one of the most severe microvascular complications of diabetes and a major cause of premature death and disability.
- Trial name
- NCT06843304
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Chinese PLA General Hospital
Diabetic Nephropathy
Study Of Diabetic Nephropathy With Atrasentan
The study objective was to evaluate the effect of atrasentan compared with placebo on time to doubling of serum creatinine (DBSC) or the onset of end-stage renal disease (ESRD) in participants with type 2 diabetes and nephropathy…
- Trial name
- SONAR (NCT01858532)
- Testing
- Atrasentan
- Volunteers
- 5,107 people
- Sponsor
- AbbVie
Chronic Kidney Disease, Diabetic Nephropathy
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
The study objective is to investigate the effects of three low doses of atrasentan on urinary albumin/creatinine ratio (UACR) levels in subjects with Type 2 diabetic nephropathy.
- Trial name
- NCT00920764
- Testing
- 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD, 1.75 mg Atrasentan QD
- Where
- 28 sites in United States, Puerto Rico
- Volunteers
- 92 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Diabetic Nephropathy
Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of CTP-499 following single dose administration.
- Trial name
- NCT01328821
- Testing
- CTP-499
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Concert Pharmaceuticals
Diabetic Kidney Disease, Obesity
Metabolic Phenotypes of Obesity and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus
1. Comparison between the 4 groups of metabolic phenotypes of obesity as regard the presence and frequency of DKD 2. Relation between DKD , obesity (BMI) and metabolic risk factors in patients with type 2 DM
- Conditions
- Diabetic Kidney Disease, Obesity, Metabolic Syndrome, Diabetes Mellitus, Type 2
- Trial name
- NCT06591104
- Testing
- 24 hour urinary protein
- Volunteers
- 71 people
- Sponsor
- Assiut University
Diabetic Nephropathy
Colchicine for Diabetic Nephropathy
Patients with diabetic nephropathy and proteinuria, despite maximal anti- hypertensive and anti-glucose treatment, will receive colchicine for six months, 2 mg a day, during which their 24 hour urine protein and renal function…
- Trial name
- NCT01005121
- Testing
- colchicine
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Prof.Avi Livneh
Diabetes Mellitus, Type 2
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic…
- Trial name
- NCT02864914
- Testing
- Empagliflozin, DPP-4 inhibitors
- Where
- United Kingdom
- Volunteers
- 333,580 people
- Sponsor
- Boehringer Ingelheim